Objectives: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) may be cannulated using either central (cannulation of aorta) or peripheral (cannulation of femoral or axillary artery) access. The ideal cannulation approach for postcardiotomy cardiogenic shock (PCS) is still unknown. The aim of this study is to compare the outcome of patients with PCS who were supported with central vs. peripheral cannulation.

Methods: This is a single-center retrospective data analysis including all VA-ECMO implantations for PCS from January 2011 to December 2017. The central and peripheral approaches were compared in terms of patient characteristics, intensive care unit (ICU) stay, hospitalization length, adverse event rates, and overall survival.

Results: Eighty-six patients met the inclusion criteria. Twenty-eight patients (33%) were cannulated using the central approach, and 58 patients (67%) were cannulated using the peripheral approach. Forty-three patients (50%) received VA-ECMO in the operating room and 43 patients (50%) received VA-ECMO in the ICU. Central VA-ECMO group had higher EuroSCORE II ($p = 0.007$), longer cross-clamp time ($p = 0.054$), higher rate of open chest after the procedure ($p < 0.001$), and higher mortality rate ($p = 0.02$). After propensity score matching, 20 patients in each group were reanalyzed. In the matched groups, no statistically significant differences were observed in the baseline characteristics between the two groups except for a higher rate of open chest in the central ECMO group ($p = 0.02$). However, no significant differences were observed in the outcome and complications between the groups.

Conclusions: This study showed that in postcardiotomy patients requiring VA-ECMO support, similar complication rates and outcome were observed regardless of the cannulation strategy.

Keywords: ECMO, cardiogenic shock, postcardiotomy, cannulation, low cardiac output
INTRODUCTION

The application of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with refractory isolated cardiac or cardiopulmonary failure is increasing (1). Among high-risk patient populations requiring VA-ECMO support include patients with postcardiotomy cardiogenic shock (PCS). As all of these patients have open heart surgery, there are two main modalities to implant the VA-ECMO in these patient populations. These modalities include either central cannulation of the right atrium and ascending aorta or peripheral cannulation, most commonly via the femoral vein and artery. Alternative approaches may include the placement of a vascular prosthesis in the ascending aorta for central access (2) or, for peripheral access cannulation of the axillary artery, either directly or through a vascular prosthesis.

The optimal cannulation strategy for VA-ECMO, in terms of survival as well as myocardial recovery, management, and complication rates, remains controversial (3). Despite the considerable numbers of studies on VA-ECMO application, only a few have addressed access-related issues as primary focus in their studies (2, 4, 5). In the largest single-center series to date, Rastan et al. (6) reported no advantage of different cannulation sites by means of survival in 517 patients who required VA-ECMO after cardiac surgery, although there has been a general consensus favoring the peripheral approach (2, 6–8). Meanwhile, a recent study demonstrated that a central approach should be considered as a viable alternative in terms of complication rates (9). Based on the controversies above, we aimed to compare the outcomes of the patients with PCS who were mechanically supported with central vs. peripheral VA-ECMO.

MATERIALS AND METHODS

Definitions and Data Assessment

Inclusion and Exclusion Criteria

The inclusion criteria were adult patients (aged > 18 years) who underwent VA-ECMO implantation after elective, urgent, or emergency cardiac surgery either immediately or a few hours after arrival in the intensive care unit (ICU). Exclusion criteria were patients on VA-ECMO prior to index cardiac procedure, patients requiring venovenous (VV)-ECMO, and patients after heart transplantation and/or ventricular assist device implantation. The study protocol was approved from the corresponding institutional ethics committee (Study number: 2018-33-RetroDEuA).

PCS was defined as cardiac failure that results in the inability to wean from cardiopulmonary bypass (CPB) or cardiac failure that appears in early postoperative period under optimized inotropic and vasopressor support. Hypotension, persistent lactatemia as a sign of an end-organ malperfusion, and oliguria were the clinical parameters for the diagnosis, which was supported by an echocardiographic assessment in each patient and hemodynamic monitoring with Swan-Ganz catheterization in most cases.

Central cannulation was defined as the cannulation involving the aorta and right atrium either directly or through percutaneously placed cannula through the femoral veins. Peripheral cannulation was defined as the cannulation of the femoral or subclavian artery and femoral vein.

Bleeding was defined as any bleeding requiring reoperation. Peripheral vascular (PV) complication was defined as any extremity complication involving the vascular access (excluding groin infection). Notably, all patients with peripheral VA-ECMO cannulation technique were supported with distal leg perfusion catheter to avoid limb ischemia. Postoperative gastrointestinal (GI) complication was defined as postoperative new-onset GI bleeding or ischemia requiring surgery. Postoperative neurological injury was defined as any neurological complication including transient ischemic attack, non-disabling or disabling stroke, and global brain ischemia. Postoperative liver failure was defined as an acute increase in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin.

The following data were assessed: patient characteristics, type of the cardiac procedure, urgent or emergency procedure, cross-clamp time, CPB time, EuroSCORE II, VA-ECMO support duration, place of VA-ECMO implantation (intraoperative or in the ICU), and rate of chest being left open at the primary surgery. Furthermore, the following postimplantation data were documented: chest tube output in the first 24 h after implantation, bleeding requiring a reoperation, number of red blood cell (RBC) units given, new onset of renal dialysis, postoperative neurological injury, liver failure, and GI and PV complications. Weaning and explantation rate from ECMO, duration of ICU stay, and mortality rate after ECMO implantation were documented and compared between both groups.

Statistical Analysis

Using the SPSS statistical package and in order to test the effect of the ICU stay, hospitalization length, adverse event rates, and overall survival on the two groups (central and peripheral approach) of patients, a two-way MANOVA was performed. If the p-value is <0.05, we reject the null hypothesis that there is no difference between the means and conclude that a significant difference does.

Propensity score (PS) matching was performed as previously reported (10). Briefly, the PSs were computed by binary logistic regression. A 1:1 nearest neighbor matching algorithm with a caliper of 0.1 of the standard deviation of the logit of the PS was chosen to achieve the highest possible representativeness and precision. Risk factors, which were statistically insignificant at baseline, were not considered as confounders and therefore not adjusted by PS matching. As 46 patients did not meet the matching criteria, they were discarded from the final analysis. Finally, the residual imbalances of covariates after matching were assessed by univariate tests, the Hansen–Bowers test and the relative multivariate imbalance measure.
Kalampokas et al. Postcardiotomy VA-ECMO: Cannulation Techniques

RESULTS

Eighty-six patients met the inclusion criteria and were included in the analysis. A total of 58 patients (67%) required peripheral cannulation and 28 patients (33%) required central cannulation for VA-ECMO. The majority of patients underwent coronary artery bypass grafting (CABG) (52%). Other primary procedures were mostly combined CABG and valve surgery (29%). The mean age was 68 ± 10 years, and 64 of the patients (73%) were male. The VA-ECMO implantation for PCS took place in 43 patients (45%) in the central V A-ECMO group, and the chest was closed in 54% of the cases.

Seven (8.1%) patients received left ventricular (LV) venting, which was placed in the right superior pulmonary vein in 71.4%, in the LV apex in 14.3%, and in the pulmonary artery in 14.3% of cases.

Table 1 demonstrates the patient characteristics and demographics. There were no significant differences between groups except for higher EuroSCORE II (19 ± 14 vs. 11 ± 10, p = 0.007) and longer CPB time (229 ± 57 vs. 180 ± 94, p = 0.01) in the central VA-ECMO group. Moreover, in a greater number of patients was chest left open after surgery in the central cannulation group (11, 39%) than that in the peripheral cannulation group (3, 5%) (p < 0.001).

Table 2 summarizes the outcome after VA-ECMO implantation. There was no significant difference in any of the postoperative parameters except for a significant higher in-hospital mortality rate in the central VA-ECMO group (79 vs. 52%, p = 0.02). Moreover, there was a non-significant trend toward a higher rate of weaning in the peripheral VA-ECMO group (29 vs. 52%, p = 0.063). There was no statistically significant difference in the resternotomy rates for bleeding between the central and the peripheral group (46 vs. 43%, respectively, p = 0.819).

Due to the fact that the groups were not identical, we decided to do a 1:1 PS matching to identify two matched groups. The following factors were included in the matching: EuroSCORE II, cross-clamp time, and type of the cardiac procedure. The PS analysis resulted in 20 patients remaining in each group (Table 3). Table 4 shows the difference in the postimplantation parameters between both groups after PS matching. Interestingly, no significant differences in postoperative bleeding (1,219 ± 651 vs. 1,143 ± 1,317 ml, p = 0.824), transfusion (48 ± 29 vs. 45 ± 31, p = 0.755), duration of ICU stay (16 ± 14 days vs. 18 ± 19 days, p = 0.638), and in-hospital mortality (75 vs. 55%, p = 0.320) were observed between the matched groups. Furthermore, the rate of PV complications prior to and after matching remains similar between the groups (11 vs. 28% and 16 vs. 25%, p = 0.100 and p = 0.695, respectively). Figures 1A,B show the Kaplan–Meier survival curve in the unmatched and matched analyses.

DISCUSSION

The main findings of this single-center study including 86 consecutive patients supported with VA-ECMO in a postcardiotomy setting can be summarized as follows:
1- In the unmatched group of patients, the central VA-ECMO group tends to have higher mortality rate after the index cardiac procedure.

2- The postimplantation morbidity and mortality remain similar between the groups after PS matching, highlighting the fact that none of the implantation technique is advantageous over the other.

3- The similar bleeding rates in the matched group may be related to chest closure in the majority of the central ECMO group.

4- The rates of PV complications are similar if distal leg perfusion is used in all patients.

The PCS is presumably an annihilating complication after cardiac surgical procedures and correlated with a soaring mortality rate. What seems to be the topmost choice for patients with refractory PCS is the VA-ECMO implantation. The ideal cannulation approach (central vs. peripheral) for PCS is yet to be defined. It was therefore the aim of this study to shed light on the appropriate configuration and cannulation strategy for ECMO.

There are both benefits and pitfalls of each cannulation strategy (16): the central cannulation ensures an antegrade flow, which may provide a better LV unloading. The peripheral one directs a retrograde flow toward the aortic valve and causes an increase in LV afterload. Moreover, it is a fundamental issue that the peripheral cannulation leads to Harlequin syndrome. On the other hand, it is a less time-consuming and less invasive technique, which allows sternal closure. Central VA-ECMO might also be initiated with the closed chest in PCS. A Dacron graft can be anastomosed to the ascending aorta, which may be tunneled to exit at the subxiphoid region, allowing patients extubation and mobilization after surgery in case of prolonged support or bridge to destination therapy. However, a potential compression of the graft along its course through the mediastinum toward the subxiphoid exit points may cause an insufficient hemodynamic support. Another possible outlet for the cannulae in closed-chest conditions may be directly through the cranial end of the sternotomy wound. This may avoid a mortality over time as well as remained a resource-consuming treatment (12–14). Despite growing worldwide experience, the overall survival to hospital discharge was 41.4% in adults in a current Extracorporeal Life Support Organization (ELSO) Registry Report (5). Therefore, there are some concerns arising about costs, benefits, and ethics.

Central and peripheral cannulation strategies are both to be utilized habitually on a PCS clinical scenario. The VA-ECMO implantation for PCS according our results took place in 43 patients (50%) in the operating room and 43 patients (50%) in the ICU, as reported in the results of this study. In case of a PCS scenario, failure from CPB weaning regularly requires the implementation of VA-ECMO and usually a central configuration can easily be inaugurated utilizing the already placed cannulas for the previous CPB. A peripheral access can be achieved percutaneously using the femoral or, less frequently, axillary or subclavian (6, 8). Sorokin et al. (3) reported previously the details on appropriate configuration and cannulation strategy for ECMO.

1. CABG
2. CABG + AKR
3. CABG + MKR ± TKR
4. AKR
5. Other procedures
6. RBC, red blood cell; GI, gastrointestinal.

Table 3

| Propensity score | Central (N = 20) Mean ± SD | Peripheral (N = 20) Mean ± SD | P-value |
|------------------|---------------------------|-------------------------------|---------|
| Age (years)      | 67 ± 10                   | 60 ± 10                       | 0.738   |
| Body mass index  | 26 ± 7                    | 27 ± 5                        | 0.799   |
| Male (n, %)      | 14 (70)                   | 14 (70)                       | 1.000   |
| EuroSCORE        | 15 ± 10                   | 16 ± 13                       | 0.694   |
| X-Clamp time (min)| 126 ± 44                  | 89 ± 53                       | 0.062   |
| CPB time (min)   | 228 ± 61                  | 204 ± 108                     | 0.448   |
| VA-ECMO duration (days) | 8 ± 8                   | 7 ± 6                          | 0.561   |
| LVEF < 30%       | 10 (50)                   | 8 (30)                        | 0.333   |
| DM               | 7 (35)                    | 7 (35)                        | 1.000   |
| AF               | 7 (35)                    | 5 (25)                        | 0.731   |
| Elective procedure | 9 (45)                  | 8 (40)                        | 1.000   |
| Immediate intraoperative VA-ECMO | 10 (50) | 9 (45)                        | 1.000   |
| Chest left open after surgery | 8 (40) | 1 (6)                          | 0.020   |
| IABP             | 8 (40)                    | 6 (30)                        | 0.741   |
| LV venting       | 2 (10)                    | 2 (10)                        | 1.000   |

Table 4

| | Central (N = 20) Mean ± SD | Peripheral (N = 20) Mean ± SD | P-value |
|-----------------|---------------------------|-------------------------------|---------|
| Chest tube outcome in first 24 h | 1,219 ± 651 | 1,143 ± 1,317 | 0.824 |
| RBC Units transfused during the stay | 48 ± 29 | 45 ± 31 | 0.755 |
| Resternotomy for bleeding | 9 (45) | 9 (45) | 1.000 |
| Postoperative new onset dialysis | 14 (70) | 15 (75) | 1.000 |
| Postoperative liver failure | 6 (30) | 8 (40) | 0.741 |
| Postoperative neurological injury | 3 (15) | 2 (10) | 0.605 |
| Postoperative GI complications | 2 (11) | 1 (5) | 0.712 |
| Weaning from VA-ECMO | 5 (25) | 9 (45) | 0.320 |
| ICU stay (days) | 16 ± 14 | 18 ± 19 | 0.638 |
| In-hospital mortality | 15 (75) | 11 (55) | 0.320 |
| Peripheral vascular complications | 3 (16) | 5 (25) | 0.695 |

CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; IABP, intra-aortic balloon pump; DM, diabetes mellitus; AF, atrial fibrillation; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; CABG, coronary artery bypass grafting; AVR, aortic valve replacement; MVR, mitral valve replacement; TVR, tricuspid valve repair.
possible cardiac compression by cannulae along their course through the mediastinum.

Mariscalco et al. (17) compared peripheral and central VA-ECMO in a retrospective study of 781 patients with PCS at 19 cardiac surgery centers. This multicenter study showed that central cannulation was associated with greater inhospital mortality than peripheral cannulation (17). Although our unmatched data support this finding, after PS matching, complication rates and outcome were similar regardless of the cannulation strategy.

The subclavian artery cannulation should provide several advantages by allowing to mimic the blood flow of the central cannulation approach in contrast to femoral artery (9, 18). The advantages include the lack of atherosclerosis, minimizing atherosclerotic embolization, and preferential delivery of oxygenated blood to the heart and brain (19). Therefore, the subclavian approach appears advisable in patients with peripheral arterial occlusive disease because of its lack of atherosclerosis in comparison to the femoral artery. Ranney et al. (9) reported a higher rate of vascular complications (particularly fasciotomy and amputation) and bleeding at the cannulation site (37.5, 30.6, and 13.9%, respectively). In that study, a trend toward a higher incidence of cerebrovascular events was also observed (9). We believe that subclavian cannulation is advantageous when longer support duration is anticipated to allow patients’ extubation and mobilization.

The hemodynamic effects and end-organ function regarding cannulation approach is not well-described in the literature. Our group (2) compared the immediate trends in hemodynamics, oxygenation, ventilation, and end-organ function of patients on either peripheral or central VA-ECMO support. No particular advantage of one technique over the other was observed. The course of serum lactate levels under ECMO plays a predictive role in 30-day mortality (20, 21). However, there were no differences between peripheral and central cannulation regarding the mean peak lactate level as a marker of tissue perfusion and end-organ damage (7). In a series of 517 patients reported by Rastan et al. (6), lactate level > 10 mmol/L immediately after ECMO implantation was a significant predictor of mortality. Persistent lactate values > 10 mmol/L were also associated with increased mortality (6). They also found that arterial cannulation site did not significantly influence hospital outcome, but percutaneous venous femoral cannulation was associated with adverse outcomes (6).

Supporting an impaired ventricle with ECMO may lead to LV overload, especially in peripheral configuration due to retrograde flow toward the LV, causing an increased afterload (22). The potential consequences of LV overload are LV dilatation, increased left atrial pressure, blood stasis, and thrombus formation in cardiac chambers and pulmonary edema (22). Despite being adopted in the minority of patients, LV venting is of paramount importance during PCS. However, the optimal method for LV venting is still unclear. Central configuration allows to place an additional cannula in the LV through the right superior pulmonary vein or LV apex. On the other hand, peripheral VA-ECMO in closed-chest conditions may need another method. Intra-aortic balloon pump (IABP), although controversial (22, 23), is still being widely used in clinical practice. In some PCS series, the non-use of IABP was associated with a trend to worse survival (6, 24), whereas the others did not find any differences in survival outcomes (25, 26). Alternative techniques for percutaneous LV venting include Impella® (ABIOMED Inc., Danvers, Massachusetts) or pulmonary artery venting (22, 25, 26). The optimal combination of either peripheral or central cannulation and venting methods needs further research.

Beside its life-saving effect, complications of VA-ECMO are numerous and impair the overall outcomes inevitably (6, 11). Our single-center experience does not favor central or peripheral cannulation in terms of reoperation for bleeding and number of transfused RBC units. Regardless of cannulation strategy, bleeding, transfusion, and revision for bleeding constitute major
problems on VA-ECMO (6). Recently, Djordjevic et al. (27) reported a reexploration rate of 93% of all patients on central VA-ECMO. Central cannulation is opted for by virtue of the following: to leave the chest open to avoid tamponade as well as to allow cardiac edema to resolve, to inherit the previously inserted cannulae for ECMO circuit, and to avoid limb ischemia due to femoral artery cannulation. We expected to see more bleeding complications in the central VA-ECMO group. However, our data support the fact that the bleeding issue in the postcardiotomy setting may be rather derived by the ECMO-related bleeding tendency than the surgical technique implantation. Furthermore, another explanation may be the fact that we tend to use a prosthesis in the majority of central VA-ECMO patients to facilitate chest closure (2). Therefore, the bleeding rate was not significantly higher in the central VA-ECMO group because bleeding from sternal edges was precluded.

The present study showed that PV complications in the peripheral VA-ECMO group exceeded that of the central VA-ECMO group prior to and after matching; however, interestingly, this finding did not reach statistical significance. The main explanation of this finding is the fact that the femoral vein was frequently used as inflow cannula also for central VA-ECMO group and a distal leg perfusion catheter was used in the peripheral VA-ECMO group to avoid limb ischemia. In our study, the majority of the implantation (58.6%) was percutaneous. Loforte et al. (28) showed that central cannulation in PCS resulted in increased bleeding and continuous VV hemofiltration rates compared to peripheral access (62.7 vs. 48.4% and 56.8 vs. 43.6%, respectively). Ko et al. (8) investigated a higher rate of neurologic complication with open femoral ECMO. However, after matching the groups, no significant differences in these morbidities were observed in the present study.

Limitations
The main limitation of this study is its retrospective single-center nature. However, the majority of the data were already prospectively collected in the hospital database. Moreover, the implantation approach was not randomized, and the decision regarding central vs. peripheral cannulation was at the discretion of the implanting surgeon in the operating room. However, ECMO implantations in the ICU were performed exclusively peripherally at the bed site. Furthermore, no hemodynamic data or data on vasopressor requirement were available to compare between the groups. After PS matching, a large number of patients were discarded from the analysis, which may potentially influence the results.

CONCLUSION
This study of a matched group of patients using central vs. peripheral VA-ECMO for postcardiotomy patients showed no advantage of one approach over the other. The high rate of chest closure in the central VA-ECMO group and the exclusive implication of the distal leg perfusion catheter may explain this finding. Decision-making for the cannulation strategy should be individualized and adjusted to the clinical scenario. Further randomized studies are necessary to identify the ideal cannulation strategy in the PCS population.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Ethic Committee of University Hospital of Düsseldorf. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR'S NOTE
Presented in part at the 32nd EACTS Annual Meeting in Milan, Italy.

AUTHOR CONTRIBUTIONS
NK: conceptualization, data curation, formal analysis, investigation, methodology, and writing—original draft. NS: data curation, supervision, writing—original draft, writing—review and editing, and project administration. GP: formal analysis and writing—review and editing. HA, PA, AA, RW, and AL: writing—review and editing. DS: conceptualization, methodology, supervision, writing—original draft, and writing—review and editing. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Lawler PR, Silver DA, Scirica BM, Couper GS, Weinhouse GL, Camp PC Jr. Extracorporeal membrane oxygenation in adults with cardiogenic shock. Circulation. (2015) 131:676-80. doi: 10.1161/CIRCULATIONAHA.114.006647
2. Saeed D, Stosik H, Islamovic M, Albert A, Kamiya H, Maxhera B, et al. Femoro-femoral versus atrio-aortic extracorporeal membrane oxygenation: selecting the ideal cannulation technique. Artif Organs. (2014) 38:549-55. doi: 10.1111/aor.12245
3. Sorokin V, MacLaren G, Vidanapathirana PC, Delnoij T, Lorusso R. Choosing the appropriate configuration and cannulation strategies for extracorporeal membrane oxygenation: the potential dynamic process of organ support and importance of hybrid modes. Eur J Heart Fail. (2017) 19:75-83. doi: 10.1002/ejhf.849
4. Biancari F, Perrotti A, Dalên M, Guerrieri M, Fiore A, Reichart D, et al. Meta-analysis of the outcome after postcardiotomy venoarterial extracorporeal membrane oxygenation in adult patients. J Cardiothorac Vasc Anesth. (2018) 32:1175–82. doi: 10.1053/j.jvca.2017.08.048
5. Lorusso R, Gelsomino S, Parise O, Mendiratta P, Prodhán P, Rycus P, et al. Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock in elderly patients: trends in application and outcome from the Extracorporeal Life Support Organization (ELSO) Registry. *Ann Thorac Surg.* (2017) 104:62–9. doi: 10.1016/j.athoracsur.2016.10.023

6. Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. *J Thorac Cardiovasc Surg.* (2010) 139:302–11. doi: 10.1016/j.jtcvs.2009.10.043

7. Kanji HD, Schulze CJ, Orepoulos A, Lehr EJ, Wang W, MacArthur RM. Peripheral versus central cannulation for extracorporeal membrane oxygenation: a comparison of limb ischemia and transfusion requirements. *Thorac Cardiovasc Surg.* (2010) 58:459–62. doi: 10.1055/s-0030-1250005

8. Ko WJ, Lin CJ, Chen RJ, Wang SS, Lin FY, Chen YS. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. *Ann Thorac Surg.* (2002) 73:538–45. doi: 10.1016/S0003-4975(01)03330-6

9. Ranney DN, Benrashid E, Meza JM, Keenan JE, Bonadonna DK, Bartz R, et al. Central cannulation as a viable alternative to peripheral cannulation in extracorporeal membrane oxygenation. *Semin Thorac Cardiovasc Surg.* (2017) 29:188-95. doi: 10.1053/j.semtcvs.2017.02.007

10. Petrov G, Kelle S, Fleck E, Wellnhofer E. Incremental cost-effectiveness of dobutamine stress cardiac magnetic resonance imaging in patients at intermediate risk for coronary artery disease. *Clin Res Cardiol.* (2015) 104:401–9. doi: 10.1007/s00392-014-0793-0

11. Whitman GF. Extracorporeal membrane oxygenation for the treatment of postcardiotomy shock. *J Thorac Cardiovasc Surg.* (2017) 153:95–101. doi: 10.1016/j.jtcvs.2016.08.024

12. Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support: Incidence, outcomes, and cost analysis. *J Am Coll Cardiol.* (2014) 64:1407–15. doi: 10.1016/j.jacc.2014.07.958

13. McCarthy F, McDermott C, Kini V, Gutsche JT, Waldo JW, Xie D, et al. Trend in US extracorporeal membrane oxygenation use and outcomes: 2002–2012. *Semin Thorac Cardiovasc Surg.* (2015) 27:81–8. doi: 10.1055/s-0035-1555005

14. Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. *Intensive Care Med.* (2016) 42:889–96. doi: 10.1007/s00134-016-4273-z

15. Javidfar I, Brodie D, Costa J, Miller J, Jurado J, LaVelle M, et al. Subclavian artery cannulation for venoarterial extracorporeal membrane oxygenation. *ASAIO J.* (2012) 58:494–8. doi: 10.1097/MAT.0b013e318268ea15

16. Raffa GM, Kowalewski M, Brodie D, Ogino M, Whitman G, Meani P, et al. Meta-analysis of peripheral or central ECMO in postcardiotomy shock. *Ann Thorac Surg.* (2019) 107:311–21. doi: 10.1016/j.athoracsur.2018.05.063

17. Mariscalco G, Salsano A, Fiore A, Dalim M, Ruggieri VG, Saeed D, et al. Peripheral versus central extracorporeal membrane oxygenation for postcardiotomy shock: multicenter registry, systematic review, and meta-analysis. *J Thorac Cardiovasc Surg.* (2020) 160:1207–16. doi: 10.1016/j.jtcvs.2019.10.078

18. Chiconte S, Rosenzweig EB, Brodie D, Bacchetta M. The “Central Sport Model”: extracorporeal membrane oxygenation using the innominate artery for smaller patients as bridge to lung transplantation. *ASAIO J.* (2017) 63:e39-44. doi: 10.1097/MAT.0000000000000427

19. Chamogeorgakis T, Lima B, Shafii AE, Nagpal D, Pokersnik JA, Navia JL, et al. Outcomes of axillary artery side graft cannulation for extracorporeal membrane oxygenation. *J Thorac Cardiovasc Surg.* (2013) 145:1088–92. doi: 10.1016/j.jtcvs.2012.08.070

20. Rigamonti F, Monteucco F, Boroli R, Rey F, Gencer B, Cikirikcioglu M, et al. The peak of blood lactate during the first 24h predicts mortality in acute coronary syndrome patients under extracorporeal membrane oxygenation. *Int J Cardiol.* (2016) 221:741–5. doi: 10.1016/j.ijcard.2016.07.065

21. Slottosch J, Liakopoulos O, Kuhn E, Scherner M, Deppe AC, Sabashnikov A, et al. Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shock. *J Crit Care.* (2017) 42:35–41. doi: 10.1016/j.jcrc.2017.06.022

22. Meani P, Gelsomino S, Natour E, Johnson DM, Rocca H, Pappalardo F, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. *Eur J Heart Fail.* (2017) 19:84–91. doi: 10.1002/ejhf.850

23. Cheng R, Hachamovitch R, Makkar R, Ramzy D, Moriguchi JD, Arabia FA, et al. Lack of survival benefit found with use of intraaortic balloon pump in extracorporeal membrane oxygenation: a pooled experience of 1517 patients. *J Invasive Cardiol.* (2015) 27:453–8.

24. Smedira NG, Blackstone EH. Postcardiotomy mechanical support: risk factors and outcomes. *Ann Thorac Surg.* (2001) 71:S60–6. doi: 10.1016/S0003-4975(00)02626-6

25. Distelmaier K, Wiedemann D, Binder C, Haberi T, Zimper D, Heinz G, et al. Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. *J Thorac Cardiovasc Surg.* (2018) 155:2471–6. doi: 10.1016/j.jtcvs.2017.12.079

26. Mikus E, Tripodi A, Calvi S, Giglio MD, Cavallucci A, Lamarra M, Centri Mag venoarterial extracorporeal membrane oxygenation support as treatment for patients with refractory postcardiotomy cardiogenic shock. *ASAIO J.* (2013) 59:18–23. doi: 10.1097/MAT.0b013e3182768b68

27. Djordjevic I, Eghbalzadeh K, Sabashnikov A, Deppe AC, Kuhn E, Merkle J, et al. Central vs peripheral venoarterial ECMO in postcardiotomy shock. *J Card Surg.* (2020) 35:1037–42. doi: 10.1111/jocs.14526

28. Loforte A, Martinelli G, Musumeci F, Folesani G, Pilato E, Martin Suarez S, et al. Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors. *Artif Organs.* (2014) 38:129-41. doi: 10.1111/aor.12317

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kalampokas, Sipahi, Aubin, Akhyari, Petrov, Albert, Westenfeld, Lichtenberg and Saeed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.